Indication
Bone Marrow Transplant Complications
2 clinical trials
2 products
2 drugs
Clinical trial
Phase I/II Trial of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationStatus: Withdrawn, Estimated PCD: 2025-12-01
Drug
SitagliptinProduct
BortezomibDrug
cyclophosphamideClinical trial
The Genetic Contribution to Progression of Kidney DiseaseStatus: Recruiting, Estimated PCD: 2040-05-19
Product
Genetic Polymorphisms